Harvard Bioscience (HBIO) Gross Profit (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Gross Profit data on file, last reported at $12.2 million in Q1 2026.

• On a quarterly basis, Gross Profit changed 0.49% year-over-year to $12.2 million in Q1 2026; TTM through Mar 2026 was $50.0 million, a 4.23% decrease from a year earlier, with the FY2025 full-year figure at $49.9 million, down 8.87% from the prior year.
• Gross Profit for Q1 2026 stood at $12.2 million, down from $14.2 million in the prior quarter.
• Over the last five years, Gross Profit for HBIO reached as high as $18.3 million in Q1 2023 and fell as low as $11.5 million in Q2 2025.
• Historically, Gross Profit has averaged $14.3 million across 5 years, with a median of $14.2 million in 2025.
• Across the five-year window, Gross Profit retreated 25.36% in 2022 and rose 20.99% in 2023, its largest moves.
• Year by year, Gross Profit stood at $15.8 million in 2022, then advanced by 3.11% to $16.3 million in 2023, then dropped by 14.17% to $14.0 million in 2024, then rose by 1.15% to $14.2 million in 2025, then decreased by 13.6% to $12.2 million in 2026.
• Per Business Quant data, the three most recent Gross Profit figures were $12.2 million in Q1 2026, $14.2 million in Q4 2025, and $12.0 million in Q3 2025.